Pharmacists of Uni Pharma Co., Ltd.. Wu Qianhua, Huang Junwei, Lin Liangguang
Huang Junda, manager of the medical department of Uni Pharma Co., Ltd.
Many studies have found that patients with chronic myeloid leukemia and gastrointestinal stromal tumors who take a fixed dose of imatinib in the trough blood during the stable phase have shown great variability. In addition, studies have successively found that patients with chronic myeloid leukemia and advanced gastrointestinal stromal tumors have a better response to the efficacy of patients with higher blood concentrations in the trough of imatinib. In addition to the large pharmacokinetic variation between patients, the high cost of the course of imatinib and the fact that the patient’s medication may not be as cooperative as expected and need to be taken for a long time, it is worth exploring whether the best treatment effect can be achieved by monitoring the blood concentration in the patient.
Keywords: Imatinib, Glivec, therapeutic drug monitoring, chronic myeloid leukemia, gastrointestinal stromal tumor, tyrosine kinase inhibitors
Journal of Pharmacy, Vol. 33, No. 2
THE JOURNAL OF TAIWAN PHARMACY Vol.33 No.2
